Johnson & Johnson Stock Holds Steady After China Psoriasis Approval and FDA Expansion

Johnson & Johnson's stock remains elevated in late August 2026, closing at $270.00 on August 26 as investors weigh new regulatory approvals and an improved full-year outlook.

The company has recently received approval for its oral pill Icotyde in China, expanding its reach in the world's second-largest pharmaceutical market and opening another avenue for growth in immunology therapies.

In addition, the US FDA expanded Johnson & Johnson's approval of the medicine Imaavy to treat warm autoimmune hemolytic anemia, a rare and potentially life-threatening blood disorder that affects patients aged 12 and older who are currently receiving or have previously received steroids.